Affinity Asset Advisors’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$40.7M Buy
+4,308,700
New +$34.4M 1.66% 20
2026
Q2
– Sell
-1,250,000
Closed -$9.6M – 122
2026
Q1
$9.6M Buy
+1,250,000
New +$8.56M 0.5% 53
2025
Q2
– Sell
-1,025,000
Closed -$3.09M – 100
2025
Q1
$3.09M Buy
1,025,000
+775,000
+310% +$2.35M 0.29% 55
2024
Q4
$640K Buy
+250,000
New +$1.04M 0.09% 73
2024
Q2
– Sell
-589,400
Closed -$3.17M – 112
2024
Q1
$3.17M Buy
+589,400
New +$2.67M 0.39% 64

Other funds holding IBRX

Affinity Asset Advisors's IBRX Position: Q3 2026 in Review

Affinity Asset Advisors opened a new position in ImmunityBio (IBRX) in Q3 2026: 1,180,000 shares worth $11.1M. The stake represents 0.45% of the portfolio and ranks #50 among its holdings.

405 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Affinity Asset Advisors held 1,180,000 shares of ImmunityBio worth $11.1M as of Q3 2026.
  • ImmunityBio was a new Affinity Asset Advisors position in Q3 2026.
  • ImmunityBio made up 0.45% of Affinity Asset Advisors's portfolio in Q3 2026, its #50 holding.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.